Published in Cardiovascular Business Week, June 29th, 2004
According to recent research from the United States, "Pressure-overload left ventricular hypertrophy (LVH) is characterized by an increase in myocyte size and fibrosis. However, it is not clear how each of these components affects hypertensive heart disease (HHD)."
"We have shown in two different rat models of hypertension that cardiac fibrosis can be reduced with N-acetyl-seryl-aspartyl-lysylproline (Ac-SDKP), an antifibrotic peptide normally present in mammals," wrote O.H. Cingolani and colleagues, Henry Ford...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.